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ABSTRACT: Modifications of natural DNA in a cell-free medium by antitumor monodentate Ru(II) arene
compounds of the general formula [(η6-arene)Ru(en)Cl]+ (arene ) biphenyl, dihydroanthracene,
tetrahydroanthracene,p-cymene, or benzene; en) ethylenediamine) were studied by atomic absorption,
melting behavior, transcription mapping, circular and linear dichroism, plasmid unwinding, competitive
ethidium displacement, and differential pulse polarography. The results indicate that these complexes
bind preferentially to guanine residues in double-helical DNA. The data are consistent with DNA binding
of the complexes containing biphenyl, dihydroanthracene, or tetrahydroanthracene ligands that involves
combined coordination to G N7 and noncovalent, hydrophobic interactions between the arene ligand and
DNA, which may include arene intercalation and minor groove binding. In contrast, the single hydrocarbon
rings in thep-cymene and benzene ruthenium complexes cannot interact with double-helical DNA by
intercalation. Interestingly, the adducts of the complex containingp-cymene ligand, which has methyl
and isopropyl substituents, distort the conformation and thermally destabilize double-helical DNA distinctly
more than the adducts of the three multiring ruthenium arene compounds. It has been suggested that the
different character of conformational alterations induced in DNA, and the resulting thermal destabilization,
may affect differently further “downstream” effects of damaged DNA and consequently may result in
different biological effects of this new class of metal-based antitumor compounds. The results point to a
unique profile of DNA binding for Ru(II) arene compounds, suggesting that a search for new anticancer
compounds based on this class of complexes may also lead to an altered profile of biological activity in
comparison with that of metal-based antitumor drugs already used in the clinic or currently on clinical
trials.
Platinum coordination compounds are widely used as
antitumor drugs. The first platinum antitumor drugs intro-
duced in the clinic werecis-diamminedichloroplatinum(II)1
(cisplatin) and its somewhat less toxic analogue carboplatin
[cis-diammine-1,1-cyclobutanedicarboxylatoplatinum(II)]. Both
compounds show the same spectrum of antitumor activity.
The clinical efficacy of these anticancer drugs is diminished
by intrinsic and acquired tumor resistance. Owing to these
limitations, there is an intense effort to design new transition-
metal-based compounds that are capable of overcoming
problems associated with cisplatin and carboplatin chemo-
therapy while delivering the therapeutic effect.
Cisplatin and carboplatin target cellular DNA, forming
covalent adducts (1). The most abundant adducts formed by
cisplatin in linear DNA are 1,2-d(GpG) (∼65%) or 1,2-
d(ApG) (25%) intrastrand and 1,2-d(GG) (∼6%) interstrand
cross-links (2-4). In the years following the introduction
of cisplatin, the design of new platinum antitumor drugs
concentrated mainly on direct cisplatin analogues which
adhered to the set of structure-activity relationships estab-
lished as early as 1973 (5, 6). More recently, there have been
efforts to design rationally unconventional platinum com-
plexes that violate these original structure-activity relation-
ships, such as polynuclear platinum complexes or analogues
of the clinically ineffective trans isomer of cisplatin (trans-
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design of other transition-metal antitumor agents. Possible
advantages in using transition-metal ions other than Pt(II)
include the availability of additional coordination sites in
octahedral complexes and the altered shape of the complex,
alterations in ligand affinity and substitution kinetics, changes
in oxidation state, and photodynamic approaches to therapy.
In the design of these new drugs, ruthenium complexes have
attracted much interest (10-12).
Organometallic ruthenium(II) arene complexes of the type
[(η6-arene)Ru(II)(en)Cl][PF6] (en ) ethylenediamine) con-
stitute a relatively new group of anticancer compounds (13,
14). These are pseudo-octahedral “piano-stool” complexes
with the arene ring occupying three coordination sites and
two diamine nitrogens and the halide ligand occupying the
remaining three sites. Importantly, the arene ligand is strongly
bound and stabilizes ruthenium(II): the complexes do not
readily undergo oxidation to ruthenium(III). Moreover, most
of the compounds are ionic and have a reasonable aqueous
solubility. These monodentate Ru(II) arene complexes have
been considered novel anticancer agents with a mechanism
of action different from that of the ruthenium(III) complex
(ImH)[trans-Ru(III)Cl4Im(Me2SO)] {Im ) imidazole, NAMI-
A}, which is currently on clinical trial (11, 15).
Broadening the chemotherapeutic arsenal depends on
understanding existing agents with a view toward developing
new modes of attack. Interestingly, a direct correlation
between cytotoxicity and DNA binding has already been
observed for several ruthenium compounds in cell cultures
(16). Also consistent with DNA binding in vivo, a number
of ruthenium compounds inhibit DNA replication, exhibit
mutagenic activity, induce the SOS repair mechanism, bind
to nuclear DNA, and reduce RNA synthesis (16). Similarly,
several antitumor ruthenium compounds have also been
shown (17-21) to bind to DNA and inhibit DNA replication
in vitro, but the pharmacological target for ruthenium
compounds and the mechanism underlying its biological
effects are not known.
The (η6-arene)Ru(II) bonds are inert toward hydrolysis,
but the monofunctional complexes [(η6-arene)Ru(II)(en)(Cl)]+
readily lose their chloride ligand and transform into the
corresponding, more reactive, aquated species (22). It has
also been shown (14) that the complex [(η6-p-cymene)Ru-
(II)(en)(Cl)]+ binds to a short, single-stranded deoxyriboo-
ligonucleotide (14-mer), forming monofunctional adducts,
and that the preferential sites of ruthenation in this oligo-
mer are guanine residues. To address further fundamental
questions about DNA binding modes of ruthenium(II) arene
antitumor compounds, the experiments described in the pres-
ent paper were carried out. More specifically, the interac-
tions of polymeric B-DNAs with [(η6-arene)Ru(II)(en)-
(Cl)]+ complexes [where arene) biphenyl (BIP), dihy-
droanthracene (DHA), tetrahydroanthracene (THA),p-cy-
mene (CYM), or benzene (BEN)] in cell-free media were
investigated by various biochemical and biophysical methods
with the goal to contribute to understanding their biological
effects and to help establish structure-pharmacological
relationships for this class of ruthenium anticancer com-
pounds.
MATERIALS AND METHODS
Starting Materials. [(η6-arene)Ru(II)(en)(Cl)]PF6 com-
plexes (Figure 1) were prepared as described previously (23).
Cisplatin,trans-diamminedichloroplatinum(II) (transplatin),
and chlorodiethylenetriamineplatinum(II) chloride{[Pt(dien)-
Cl]Cl} were synthesized and characterized at Lachema (Brno,
Czech Republic). The stock solutions of the ruthenium and
platinum complexes (5× 10-4 M in H2O) were prepared in
the dark at 25°C and stored for at least 7 days before they
were used. Aquation of these Ru(II) arene complexes is
relatively rapid in water (22), and as for cisplatin, the aqua
adducts are more reactive than the chloro complexes. Calf
thymus (CT) DNA (42% G+ C, mean molecular mass∼ 2
× 107) was also prepared and characterized as described
previously (24, 25). Poly(dG-dC) and poly(dA-dT) were
obtained from Amersham Pharmacia-Biotech (Piscataway,
NJ) and were used without further purification.
Plasmid pSP73KB [2455 bp (26)] was isolated according
to standard procedures and banded twice in CsCl/EtBr
equilibrium density gradients. Restriction endonucleases were
purchased from New England Biolabs (Beverly, MA).
Riboprobe Gemini System II for transcription mapping
containing SP6 and T7 RNA polymerases was purchased
from Promega (Madison, WI). Ethidium bromide (EtBr) and
agarose were from Merck KgaA (Darmstadt, Germany). The
radioactive products were from Amersham (Arlington Heights,
IL).
Metalation Reactions. CT DNA and plasmid DNAs were
incubated with ruthenium or platinum complex in 10 mM
NaClO4 (pH ∼ 6) at 37°C for 48 h in the dark, if not stated
otherwise. The number of atoms of the metal bound per
nucleotide residue (rb values) was determined by flameless
atomic absorption spectrophotometry (FAAS) (21).
DNA Transcription by RNA Polymerase in Vitro. Tran-
scription of the (NdeI/HpaI) restriction fragment of pSP73KB
DNA with SP6 or T7 RNA polymerase and electrophoretic
analysis of transcripts were performed according to the
protocols recommended by Promega (Promega Protocols and
Applications, 43-46 (1989/90)) and previously described in
detail (26, 27).
Unwinding of NegatiVely Supercoiled DNA.Unwinding
of closed circular supercoiled pSP73KB plasmid DNA was
assayed by an agarose gel mobility shift assay (28). The
unwinding angle,Φ, induced per metal-DNA adduct was
calculated upon the determination of therb value at which
the complete transformation of the supercoiled form to the
relaxed form of the plasmid was attained. Samples of pSP73
plasmid were incubated with Ru(II) arene or cisplatin in 10
mM NaClO4 at 37°C in the dark for 48 h. All samples were
precipitated by ethanol and redissolved in TAE buffer (0.04
FIGURE 1: Structures of Ru(II) arene complexes used in this work.
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M Tris-acetate+ 1 mM EDTA, pH 7.0). An aliquot of the
precipitated sample was subjected to electrophoresis on 1%
agarose gels running at 25°C in the dark with TAE buffer
with a voltage set at 30 V. The gels were then stained with
EtBr, followed by photography on Polaroid 667 film with
transilluminator. The other aliquot was used for the deter-
mination of rb values by FAAS.
Circular Dichroism (CD) and Linear Dichroism (LD).If
not stated otherwise, CD and LD spectra of DNA modified
by the ruthenium complexes were recorded at 25°C in 10
mM NaClO4 on JASCO J-720 and adapted J-715 spectro-
polarimeters.
Differential Pulse Polarography.Differential pulse po-
larographic (DPP) curves of DNA were measured after
nonmodified DNA or DNA modified by either Ru(II) arene
compound used in the present work was redissolved in a
medium consisting of 0.3 M ammonium formate plus 0.05
M phosphate (Na2HPO4/NaH2PO4) buffer, pH 6.8. DPP
curves were recorded with the aid of an EG&C PARC
electrochemical analyzer, model 384B at 25°C using the
following apparatus settings: voltage scan rate of 2 mV/s,
pulse amplitude of 5 mV, drop time of 1.0 s. The potentials
are relative to the saturated calomel reference electrode
(SCE).
Fluorescence Measurements.Fluorescence measurements
in the presence of EtBr of CT DNA modified by ruthenium
arene complexes were performed at an excitation wavelength
of 546 nm, and the emitted fluorescence was analyzed at
590 nm. The fluorescence intensity was measured at 25°C
in 0.4 M NaCl to avoid secondary binding of EtBr to DNA
(29, 30). The concentrations were 0.01 mg/mL for DNA and
0.04 mg/mL for EtBr, which corresponded to the saturation
of all intercalation sites of EtBr in DNA (29, 30). These
measurements were performed on a Shimadzu RF 40
spectrofluorophotometer using a 1 cmquartz cell.
DNA Melting.The melting curves of DNA were recorded
by measuring the absorbance at 260 nm. The melting curves
of unruthenated or ruthenated DNA were recorded after Tris-
HCl/EDTA buffer and NaClO4 were added so that the
resulting media contained 0.01-0.2 M NaClO4 with 1 mM
Tris-HCl/0.1 mM EDTA, pH 7.4. The value of the melting
temperature (tm) was determined as the temperature corre-
sponding to a maximum on the first-derivative profile of the
melting curves. Thetm values were thus determined with an
accuracy of(0.3 °C.
Other Methods.Absorption spectra were measured with
Beckmann DU-7400 and Cary 1E spectrophotometers. FAAS
measurements were carried out on a Unicam 939 AA
spectrometer with a graphite furnace. For FAAS analysis,
DNA was precipitated with ethanol and dissolved in 0.1 M
HCl.
RESULTS
DNA Binding.Solutions of double-helical CT DNA at a
concentration of 0.1 mg/mL were incubated with Ru(II) arene
complexes at anr i (molar ratio of free ruthenium complex
to nucleotide phosphates at the onset of incubation with
DNA) value of 0.1 in 10 mM NaClO4 at 37°C. At various
time intervals, an aliquot of the reaction mixture was
withdrawn, quickly cooled on an ice bath, and precipitated
by ethanol, and the content of ruthenium in the supernatant
of these samples was determined by FAAS. Figure 2 shows
a plot of rb (the number of atoms of metal bound per
nucleotide residue) against the time of DNA incubation with
Ru-BIP (r i ) 0.1). The amount of ruthenium bound per
DNA nucleotide phosphate (rb) increased with time. After
∼3 h, approximately 90% of the molecules of the Ru-BIP
present in the reaction mixture were bound to DNA. In these
binding reactions, the time at which the binding reached 50%
(t50%) was∼10, 15, and 10 min and 3.5 h for the compounds
Ru-BIP, Ru-DHA, Ru-THA, and Ru-CYM, respectively.
The value oft50% for the reaction of cisplatin with DNA under
conditions identical to those specified in Figure 2 was∼2 h
(31).
The binding of Ru(II) arene compounds to CT DNA was
also quantified in two other ways. Aliquots of the reaction
mixture withdrawn at various time intervals were quickly
cooled on an ice bath and then exhaustively dialyzed against
10 mM NaClO4 at 4 °C or filtered using Sephadex G50 to
remove free (unbound) ruthenium compound. The content
of ruthenium in these DNA samples was determined by
FAAS. Results identical to those obtained using the assay
based on DNA precipitation by ethanol were obtained.
In further experiments, CT DNA was also incubated with
the Ru(II) arene complexes atr i ) 0.2 and essentially a
similar rate of binding was observed as for the reaction at
r i) 0.1. When Ru complexes were added to a higher level
(r i ) 0.25), the DNA precipitated immediately, probably due
to electrostatic interactions between the positively charged
Ru(II) arene complexes and DNA.
The binding experiments carried out in this work indicated
that modification reactions resulted in the irreversible
coordination of the Ru(II) arene complexes to polymeric
double-helical DNA, which thus facilitated sample analysis.
Hence, it was possible to prepare easily and precisely samples
of DNA modified by the ruthenium complex at a preselected
value of rb. Thus, except where stated, samples of DNA
modified by Ru(II) arene compounds and analyzed further
by biophysical or biochemical methods were prepared in 10
mM NaClO4 at 37 °C. After 24 h of the reaction of DNA
with the complex, the samples were precipitated in ethanol
and dissolved in the medium necessary for a particular
analysis, and therb value in an aliquot of this sample was
checked by FAAS. In this way, most of the analyses
described in the present paper were performed in the absence
of unbound (free) Ru(II) arene complex.
In Vitro Transcription of DNA Containing Ru(II) Arene
Adducts.In vitro RNA synthesis by RNA polymerases on
DNA templates containing several types of bifunctional
FIGURE 2: Kinetics of the binding of the Ru(II) arene compound
Ru-BIP to calf thymus DNA. Medium: 10 mM NaClO4 at 37
°C. The concentration of DNA was 0.1 mg/mL;r i ) 0.1. Data
measured in triplicate varied on average(3% from their mean.
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adducts of platinum complexes can be prematurely termi-
nated at the level or in the proximity of adducts (26, 27).
Importantly, monofunctional DNA adducts of several plati-
num complexes are unable to terminate RNA synthesis (26,
27, 32).
Cutting of pSP73KB DNA byNdeI and HpaI restriction
endonucleases yielded a 212-bp fragment (26, 27) (a
substantial part of its nucleotide sequence is shown in Figure
3B). This fragment contained SP6 or T7 RNA polymerase
promotors [in both strands close to their 3′-ends (Figure 3B)].
The experiments were carried out using this linear DNA
fragment modified by Ru(II) arene complexes, cisplatin,
transplatin, or [Pt(dien)Cl]Cl atrb ) 0.01, for RNA synthesis
by SP6 or T7 RNA polymerase (Figure 3A, lanes BIP, DHA,
THA, CYM, cisDDP, transDDP, or dienPt, respectively).
RNA synthesis on the fragment modified by the ruthenium
and bifunctional platinum complexes yielded fragments of
defined sizes, which indicates that RNA synthesis on these
templates was prematurely terminated. The major stop sites
produced by ruthenium compounds were identical for all four
Ru(II) arene compounds Ru-BIP, Ru-DHA, Ru-THA, and
Ru-CYM (Ru-BEN was not studied in this assay) and were
mainly at guanine residues. The corresponding bands on the
autoradiogram were of similar intensity for the compounds
Ru-BIP, Ru-DHA, and Ru-THA, whereas the bands
produced by Ru-CYM were markedly less intense. For
comparative purposes, the inhibition of RNA synthesis by
DNA adducts of cisplatin, transplatin, and monofunctional
[Pt(dien)Cl]Cl is also shown (Figure 3A, lanes cisPt, transPt,
and dienPt) and demonstrates more termination for cisplatin
but at the same termination sites as those for the Ru(II)
arenes, different termination sites than those for transplatin,
and no termination of RNA synthesis by monofunctional [Pt-
(dien)Cl]Cl. The sequence analysis reveals that the major
bands resulting from termination of RNA synthesis by the
adducts of cisplatin and Ru(II) arene compounds preferen-
tially appear one or a half nucleotide preceding G sites and
to a considerably less extent preceding A sites (in AGAG
or AGGAG sequences). Taken together, Ru(II) arene com-
pounds exhibit a base sequence selectivity similar to that of
cisplatin. Nevertheless, the efficiency of the adducts of Ru-
(II) arene complexes to terminate RNA synthesis in vitro is
in general reduced relative to that of cisplatin. Furthermore,
the efficiency of the Ru-CYM complex was noticeably
lower than that of the other three ruthenium compounds
examined in this assay.
Circular and Linear Dichroism Spectroscopy.A sizable
CD spectrum can be induced into the absorbance bands of a
number of low-molecular-mass molecules upon their binding
to double-helical DNA (33). Ideally, ligand absorbance bands
that do not overlap with DNA bands (below 300 nm) are
used to probe the interaction. The Ru(II) arene compounds
investigated here are achiral (not optically active) when free
in solution. Binding of the Ru(II) arene complexes to DNA
was indicated by the induction of a sizable CD spectrum for
the Ru(II)-arene absorption bands [e.g. Ru(II) to areneπ*
charge-transfer transitions at 375 nm] in the presence of
double-helical DNA.
CD spectra for CT DNA in the absence and in the presence
of increasing amounts of Ru(II) arene compounds bound to
DNA are compared in Figure 4 (panels A-D). Binding of
the compounds Ru-BIP, Ru-DHA, and Ru-THA to CT
DNA results in the appearance of a positive CD band
centered around 370-380 nm, and its intensity increased with
the level of DNA ruthenation. Interestingly, the induced CD
signal of Ru-BIP was the largest, whereas the binding of
Ru-CYM to double-helical DNA resulted in no induced CD
band in this region (Figure 4D). The different intensities of
the induced CD bands produced by the compounds Ru-
BIP, Ru-DHA, and Ru-THA are, at least partly, due to
the different extinction coefficients (ca. 380, 280, and 150
M-1 cm-1, respectively) of the free compounds at the
wavelengths corresponding to this CD band.
Upon binding of Ru(II) arene compounds to CT DNA,
the approximately conservative CD spectrum normally found
for B-DNA at wavelengths below 300 nm (Figure 4A-D)
is also changed. As a function ofrb, there was a marked
increase in the intensity of the positive band around 280 nm
when DNA was modified by the compounds Ru-BIP, Ru-
DHA, and Ru-THA, accompanied by a decrease in the
intensity of the negative band at 245 nm (Figure 4A-C).
This induced CD signal is due to changes in both the intrinsic
DNA CD and the ligand-induced CD. On the other hand,
when DNA was modified by Ru-CYM, no such increase
FIGURE 3: Inhibition of RNA synthesis by SP6 and T7 RNA
polymerases on theNdeI/HpaI fragment of pSP73KB plasmid
modified by Ru(II) arene and platinum complexes. (A) Autorad-
iograms of 6% polyacrylamide/8 M urea sequencing gels showing
inhibition of RNA synthesis by SP6 (left) or T7 RNA polymerases
(right) on theNdeI/HpaI fragment containing adducts of ruthenium
or platinum complexes. Lanes: control, unmodified template; BIP,
DHA, THA, CYM, cisPt, transPt, and dienPt, the template modified
by Ru-BIP, Ru-DHA, Ru-THA, Ru-CYM, cisplatin, transplatin,
or [Pt(dien)Cl]Cl atrb ) 0.01, respectively; A, U, G, and C, chain
terminated marker RNAs. (B) Schematic diagram showing the
portion of the sequence used to monitor inhibition of RNA synthesis
by ruthenium and platinum complexes. The arrows indicate the start
of the SP6 and T7 RNA polymerase, which used as template the
bottom or upper strand of the NdeI/HpaI fragment of pSP73KB
DNA, respectively. (b) major stop signals (from Figure 3A) for
DNA modified by Ru-BIP. The numbers correspond to the
nucleotide numbering in the sequence map of pSP73KB plasmid.
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in the intensity of the positive band around 280 nm was seen,
but instead there was a small decrease.
We also recorded CD spectra of CT DNA and the synthetic
double-stranded polynucleotide complexes poly(dG-dC) and
poly(dA-dT) in the presence of these four Ru complexes and
also the benzene complex Ru(BEN) atr i ) 0.2. An induced
CD band at 350-410 nm was observed not only for
interaction of Ru-BIP, Ru-THA, and Ru-DHA with CT
DNA but also for interaction with poly(dG-dC) (Figure 5A
and B). For poly(dG-dC), as for CT DNA, no induced band
in the near UV region was observed for Ru-CYM, or for
Ru-BEN (Figure 5A and B). For poly(dA-dT), only the
complexes with extendedπ systems, Ru-BIP, Ru-THA,
and Ru-DHA, induced any spectral changes, and these were
small and confined to the region 260-280 nm (Figure 5C).
These small changes may be due to weak hydrophobic
interactions between the arene and the DNA bases. Neither
Ru-CYM nor Ru-BEN induced any spectral changes in
poly(dA-dT).
The flow linear dichroism data for CT DNA (Figure S1A)
resemble those of poly(dG-dC) DNA (Figure S1B) and show
that the binding of all Ru complexes causes bending of the
DNA. The three complexes Ru-THA, Ru-DHA, and Ru-
BIP cause a significant red shift (ca. 10 nm) of the main
DNA band near 260 nm, whereas the two complexes Ru-
BEN and Ru-CYM cause no shift. The wavelength shifts
in the region of DNA absorption for Ru-THA, Ru-DHA,
and Ru-BIP are consistent with intercalation of the arene
ligands, but the bending precludes full intercalation which
would rigidify the DNA and thus increase the LD. Ru-BEN
and Ru-CYM complexes rigidify poly(dA-dT) DNA with
no 260 nm band shift (Figure S1C); the other three
complexes, Ru-DHA, Ru-THA, and Ru-BIP, cause
significant bending while retaining sufficient orientation to
produce an LD signal for these compounds. Ru-DHA
FIGURE 4: CD spectroscopy of calf thymus DNA modified by
Ru(II) arene compounds. The spectra were recorded for DNA at
the concentration 30µg/mL in 10 mM NaClO4. (A-D) CD spectra
of DNA modified by Ru-BIP, Ru-DHA, Ru-THA, or Ru-CYM,
respectively. Curves in parts A-C (from the bottom to the top at
∼250,∼275, and 375 nm): 1 (- - -), control (nonmodified) DNA;
2, rb ) 0.025; 3,rb ) 0.05; 4,rb ) 0.1. Curves in part D (at∼250
nm, the order of appearance of the curves is the same as that given
for Ru-BIP, Ru-DHA, and Ru-THA in parts A-C, whereas it
is reversed at∼275 nm): 1 (- - -), control (nonmodified) DNA; 2,
rb ) 0.05; 3,rb ) 0.1; 4,rb ) 0.2. Inset in parts A-D: a part of
the CD spectrum (at 280-450 nm) recorded at a higher sensitivity
of the CD instrument. (E) Dependence of the maximum ellipticity
of the positive CD band at around 280 nm onrb: (9) Ru-BIP;
(0) Ru-DHA; (b) Ru-THA; (O) Ru-CYM. (F) Dependence of
the maximum ellipticity of the positive CD band at around∼370
nm onrb: (9) Ru-BIP; (0) Ru-DHA; (b) Ru-THA; (O) Ru-
CYM. Data points measured in duplicate varied on average(1%
from their mean.
FIGURE 5: Comparisons of the effects of different arene ligands
on the CD spectra of (A) CT DNA, (B) poly(dG-dC), and (C) poly-
(dA-dT) in 10 mM NaClO4 in the presence of various Ru(arene)
complexes atr i ) 0.2. The spectra were recorded at 25°C after
samples had been incubated for 24 h at 37°C.
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binding induces the most bending. The LD observed for the
binding to poly(dA-dT) is consistent with a mode involving
the aromatic ligands of Ru-DHA, Ru-THA, and Ru-BIP
inserted into the minor groove, giving a positive signal for
the transitions in the 260-280 nm ligand y-polarized region
and probably a negative one for the 240-255 nm z-polarized
region (according to the film LD assignments, Figure S2).
Characterization of DNA Adducts by EtBr Fluorescence.
EtBr as a fluorescent probe can be used to distinguish
intercalating and nonintercalating ligands (34). Binding of
EtBr to DNA by intercalation is blocked in a stoichiometric
manner by formation of a wide spectrum of DNA-binding
ligands including intercalators. On the other hand, modifica-
tion of DNA by monofunctional nonintercalative ligands,
such as [Pt(dien)Cl]Cl, results in only a slight decrease of
EtBr fluorescence intensity as compared with that for the
complex of nonmodified DNA with EtBr. Competitive
binding of other intercalators leads to a loss of fluorescence
because of depletion of the DNA-EtBr complex (free EtBr
is poorly fluorescent).
Double-helical DNA was modified by Ru arene com-
pounds for 24 h. The levels of the modification corresponded
to the values ofrb in the range between 0 and 0.1.
Modification of DNA by Ru-BIP, Ru-DHA, and Ru-THA
resulted in a marked decrease of EtBr fluorescence (Figure
6). In contrast, the decrease of the fluorescence intensity by
the adducts of Ru-CYM was only very small and similar
to that induced by the adducts of [PtCl(dien)]Cl (35).
DNA Unwinding.Electrophoresis in native agarose gels
was used to determine the unwinding induced in negatively
supercoiled pSP73KB plasmid DNA by monitoring the
degree of supercoiling (28) (Figure 7). A compound that
unwinds the DNA duplex reduces the number of supercoils
in closed circular DNA, which in turn causes a decrease in
the rate of migration through the agarose gel.
Figure 7 shows an electrophoresis gel from experiments
in which variable amounts of Ru-BIP were bound to a
mixture of relaxed and negatively supercoiled pSP73KB
DNA. The mean unwinding angle is given byΦ ) 18σ/rb-
(c), whereσ is the superhelical density andrb(c) is the value
of rb at which the supercoiled and nicked forms comigrate
(28). Under the present experimental conditions,σ was
calculated to be-0.063 on the basis of data for cisplatin for
which the valueΦ ) 13° was used to determinerb(c) (28).
Therb(c) values for all ruthenium arene compounds studied,
along with the mean unwinding angles calculated in this way,
are summarized in Table 1. The unwinding angles were 14
( 1° per bound Ru-BIP, Ru-DHA, and Ru-THA, and 7
( 0.5° for Ru-CYM.
DNA Melting. CT DNA was modified by Ru(II) arene
compounds added at variousrb values (0-0.1) in 10 mM
NaClO4 at 37°C for 24 h. The salt concentration was then
further adjusted by addition of NaClO4 to values in the range
0.01-0.1 M. The effect ontm is dependent both on the
amount of ruthenium bound and on the salt concentration.
At low concentrations of NaClO4 (0.01 M) an increase intm
was observed for the three compounds Ru-BIP, Ru-DHA,
and Ru-THA, and this became more pronounced with
increasingrb values (Figure 8A-C). With increasing ionic
strength, the enhancement oftm (∆tm) due to the presence
of the Ru compounds decreased, and at salt concentrations
of 0.2 M, tm decreased. In contrast, the melting behavior of
DNA modified by Ru-CYM resulted in a similar decrease
of tm at all ionic strengths (Figure 8D).
Differential Pulse Polarography.This is a sensitive method
for distinguishing between nondenaturational and denatur-
ational conformational alterations in DNA induced by various
physical or chemical agents (36). The analysis is based on
the observation that intact double-helical DNA is polaro-
graphically inactive because its reduction sites are involved
in hydrogen bonds and are unable to make contact with the
working electrode in a manner suitable for electron transfer.
Electroreduction of adenine or cytosine residues present in
distorted but still double-stranded (nondenatured) regions of
DNA is responsible for the appearance of the small DPP
peak II (Figure 9A, curve 1). Base residues in these distorted
regions become more accessible for electroreduction at the
mercury electrode and can yield a small polarographic
current. On the other hand, the appearance of a more negative
peak III in DPP curves of DNA indicates the presence of
single-stranded, denatured regions in the DNA molecule, in
which hydrogen bonds between complementary bases have
been broken (36). Differences in the adsorption properties
of double-helical and denatured DNA at the mercury
electrode have been suggested to give rise to the different
reduction potentials observed for the two DNA conforma-
tions. Importantly, less than 1% of the denatured material
in the presence of an excess of double-helical DNA can be
determined by DPP (37).
FIGURE 6: Dependences of the EtBr fluorescence onrb for DNA
modified by Ru(arene) complexes in 10 mM NaClO4 at 37°C for
24 h: (×) Ru-BIP; (]) Ru-DHA; (3) Ru-THA; (O) Ru-CYM.
Data points measured in triplicate varied on average(2% from
their mean.
FIGURE 7: Unwinding of supercoiled pSP73KB plasmid DNA by
the compound Ru-BIP. The plasmid was incubated with the
ruthenium complex for 24 h at 37°C. Lanes: 1 and 10, control,
nonmodified DNA (rb ) 0); 2, rb ) 0.03; 3,rb ) 0.06; 4,rb )
0.08; 5,rb ) 0.10; 6,rb ) 0.11; 7,rb ) 0.13; 8,rb ) 0.16; 9,rb )
0.17. The top bands correspond to the form of nicked plasmid, and
the bottom bands, to the closed, negatively supercoiled plasmid.
Table 1: Unwinding of Supercoiled pSP73KB DNA by Ru(II)
Arene Complexes
compd rb(c) unwinding anglea
Ru-BIP 0.08( 0.005 14( 1°
Ru-DHA 0.08( 0.005 14( 1°
Ru-THA 0.08( 0.005 14( 1°
Ru-CYM 0.16( 0.01 7( 0.5°
a The unwinding angle was calculated as described in the text.
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DPP has already been used to analyze DNA modified by
various physical or chemical agents, including platinum and
ruthenium compounds with different clinical efficacy (20,
38, 39). It has been found that DNA globally modified by
antitumor cisplatin, its antitumor analogues, orcis- or trans-
[RuCl2(Me2SO)4] at rb values up to 0.05 yields the more
positive DPP peak II, indicating that these antitumor drugs
induce nondenaturational conformational changes in DNA
(38). In contrast, the more negative peak III is evident on
DPP curves of DNA globally modified by clinically inef-
fective transplatin and other inactive platinum(II) complexes,
indicating that the clinically ineffective platinum complexes
induce denaturational conformational alterations in DNA
(38, 39).
DPP analysis also sheds considerable light on the confor-
mational basis for DNA binding of the Ru(II) arene
compounds tested in this work. Modification of CT DNA
by Ru-BIP, Ru-DHA and Ru-THA at rb values of
0.0005-0.01 resulted in an increase in intensity of the DPP
peak II with increasing levels of the modification (shown
for Ru-DHA in Figure 9B). The more negative peak III
was not detected even for the DPP curves recorded for DNA
modified at the highestrb value used in our experiments
(0.01). As regards the DPP analysis of DNA modified by
Ru-THA, peak II was markedly distorted by a current
corresponding to the higher background electrolyte discharge,
so that the measurement of the height of this peak II atrb
values of 0.001 and higher was impossible. On the other
hand, it was clear even from these distorted DPP curves that
no peak III was present even atrb ) 0.01. It could be argued
that the absence of peak III on the DPP curves recorded for
the samples of DNA modified by Ru-BIP, Ru-DHA and
Ru-THA at relatively highrb values (∼0.02) could be due
to an increase in the slope of the part of the DPP curve
corresponding to the background electrolyte discharge (Fig-
ure 9B, curve 4). The fact that peak III was not buried under
the background electrolyte discharge curve was verified using
the samples of DNA modified by Ru-BIP, Ru-DHA or
Ru-THA at rb ) 0.01 to which 0.8% thermally denatured
calf thymus DNA was added. For this sample, a small, more
negative peak III on the DDP curve (recorded under
conditions specified for curve 4 in Figure 9B) was clearly
observed (not shown). Thus, the absence of peak III on the
DPP curves of DNA modified by Ru-BIP, Ru-DHA, or
Ru-THA suggests that these ruthenium complexes induce
nondenaturational conformational distortions in DNA at
relatively low levels of the global modification (rb e 0.01),
a behavior similar to that for the antitumor drug cisplatin
and its antitumor analogues (38, 39). In contrast, a relative
increase in the intensity of peak II due to the global
modification by Ru-CYM was also seen, but only at lower
levels of the DNA modification (rb e 0.005) (Figure 9C).
At higher levels of DNA modification by Ru-CYM, a well-
developed more negative DPP peak III, characteristic of the
formation of single-stranded segments in double-helical
FIGURE 8: Plots showing the dependence of∆tm values onrb for
calf thymus DNA modified by Ru(II) arene compounds: A, Ru-
BIP; B, Ru-DHA; C, Ru-THA; D, Ru-CYM. The melting curves
were measured in 0.01 M (9), 0.05 M (0), 0.1 M (b), or 0.2 M
(O) NaClO4 plus 1 mM Tris-HCl with 0.1 mM EDTA, pH 7.4.
∆tm is defined as the difference between them values of ruthenated
and nonmodified DNAs. Data measured in triplicate varied on
average(2% from their mean.
FIGURE 9: Differential pulse polarographic analysis of CT DNA
modified by Ru(II) arene compounds. Double-helical DNA at a
concentration of 0.32 mg/mL in 0.3 M ammonium formate with
0.01 M phosphate buffer, pH 6.8. (A) DPP curves of nonmodified
DNA: 1, double-helical DNA; 2, thermally denatured DNA at the
concentration of 0.030 mg/mL. (B and C) DPP curves of double-
helical DNA modified by Ru-DHA (B) and Ru-CYM (C) at the
following rb values: 1, 0.0005; 2, 0.001; 3, 0.005; 4, 0.01. The
arrows in parts A-C marked by II and III indicate the potentialsE
[against saturated calomel electrode (SCE)] at which native or
denatured DNA samples yielded DPP peaks II or III, respectively
(see the text). The procedure used to measure the height of the
DPP peak (x) in the present work is shown in Figure 9A, curve 1.
(D) Dependence of the relative height of the DPP peak II,∆ ,
yielded by DNA modified by the ruthenium complexes onrb: (9)
Ru-BIP; (0) Ru-DHA; (O) Ru-CYM. The value of∆I was
calculated as the ratio of the peak height yielded by the modified
DNA over the peak height yielded by the control (nonmodified)
DNA.
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DNA, was observed. This finding supports the view that the
DNA binding mode of Ru-CYM is different from that of
the BIP, DHA, and THA ruthenium arene compounds and
that the modification by Ru-CYM may even lead to
denaturational distortions of DNA.
DISCUSSION
Our studies of the binding of the Ru(II) arene ethylene-
diamine complexes Ru-BIP, Ru-DHA and Ru-THA to
natural double-helical CT DNA show that the reactions are
about an order of magnitude faster than that for cisplatin
(Figure 2). However, the rate of binding is markedly
dependent on the type of arene ligand: binding of Ru-CYM,
a complex with a single arene ring and methyl and bulky
isopropyl substituents, binds to CT DNA more slowly than
cisplatin. The binding is almost quantitative in each case
(>90% after 24 h), and the DNA-Ru adducts are stable,
with little loss of bound Ru after extensive dialysis.
Transcription mapping experiments (Figure 3) have shown
that guanine residues are the preferential binding sites when
polymeric DNA is modified with Ru(II) arene complexes in
a random fashion.
The selectivity of these pseudo-octahedral Ru(II) arene
ethylenediamine complexes for G bases was also found
previously in our studies of model reactions of monomeric
nucleosides and nucleotides (23, 40). Ru(II) in arene ethyl-
enediamine complexes bind strongly to GN7, and C6O of
G can then form a strong intramolecular H-bond with an
NH of the coordinated ethylenediamine (23, 40). For adenine
and cytosine unfavorable interactions between the amino
groups on these bases and the amino groups of coordinated
en have been demonstrated (23, 40). Binding to thymine N3
requires displacement of the N3H proton, which is not
favorable at pH values in the physiological range and not
accessible in double-helical DNA. Also, when the arene
contains an extendedπ-electron system, as in biphenyl or
the anthracene derivatives studied in this work, an additional
stabilization of the interaction can arise from hydrophobic
π-π stacking of the coordinated arene ring system with the
purine ring (23, 40). Such hydrophobicπ-π stacking is
enhanced when one or both partners are electron-poor (41).
Ru(II) binding to G N7 decreases the electron density on
the purine but increases electron density on Ru(II) which,
in turn, enhancesπ-back-bonding of Ru(II) to theη6-arene
(42).
Slower reactions between CT DNA and Ru-CYM (Figure
1), or Ru-BEN, compared to Ru-BIP, Ru-DHA and Ru-
THA are expected from our model studies of the kinetics of
binding of these complexes to cyclic-3′,5′-GMP (23). Reac-
tions of Ru-BIP, Ru-DHA and Ru-THA with cGMP are
greater than three times faster. This difference may arise from
the ability of the extendedπ system of the arene ligand in
the faster-reacting complexes to take part in hydrophobic
π-π stacking interactions with the purine ring of G, as
observed in model complexes. This is not possible for the
monoarene complexes Ru-CYM or Ru-BEN, since the
π-electron system of these ligands is fully involved in
coordination to Ru(II). Hence, it is reasonable to suggest that
hydrophobic interactions can contribute to the driving force
for the binding of chloro Ru(II) arene complexes to double-
helical DNA.
By analogy with the changes in the CD spectra and DPP
behavior of DNA modified by cisplatin and antitumor-
inactive transplatin or [Pt(dien)Cl]Cl, it is reasonable to
suggest that the binding of Ru-BIP, Ru-DHA, and Ru-
THA results in conformational alterations in double-helical
DNA of nondenaturational character, as is the case for DNA
modification by antitumor cisplatin (38). The CD and DPP
results (Figures 4, 5, and 9) also suggest that the conforma-
tional changes induced in DNA by Ru-CYM and Ru-BEN
are different from those induced by the other three ruthenium
arene compounds and, in contrast, are of denaturational
character, similar to the case of DNA modification by
transplatin or monofunctional [Pt(dien)Cl]Cl complexes. The
LD data (Figures S1 and S2) showed that Ru-CYM stiffened
poly(dA-dT) DNA, while the other complexes bend it, and
for Ru-BIP, Ru-DHA, and Ru-THA the main effect of
binding to poly(dG-dC) and CT-DNA appears to be the
induction of DNA bending, making it difficult to draw
conclusions about the local orientations of the complexes
on the DNA. The coordination of Ru-BIP, Ru-DHA, or
Ru-THA to double-helical DNA also results in the appear-
ance of a CD band centered around 370-380 nm (Figure
4A-C). The induced CD bands for achiral molecules bound
to DNA arise either from coupling between the dipole
transition moment of the nucleobases and the bound metal
complex or from distortion of the geometry of the metal
complex. Since binding of neither Ru-CYM (Figure 4D)
nor Ru-BEN (Figure 5) to DNA gives rise to such a CD
band in this region of the spectrum, and these complexes
contain only a single ring, it seems likely that the metal-
centered induced band is related either to intercalation of
the extended arene ligands into DNA or to groove binding.
The observation of such bands is well documented for other
intercalating metal complexes (43, 44). For example, the
binding of [Pt(terpyridine)(CH3)]+ to DNA at r i ) 0.1 gives
rise to positive CD bands at 315-340 nm, indicating possible
intercalation of the terpyridine ligand (45). Similar CD bands
were observed for binding of Ru(II) arene complexes to poly-
(dG-dC) as for CT DNA (Figure 5A,B), but not for poly-
(dA-dT) (Figure 5C). From model studies of mononucle-
otides (23, 40), only weak binding to A or T is expected,
accounting for the differences in binding to poly(dA-dT).
From the assignments made by film LD experiments, the
effects on the LD spectrum of poly(dA-dT) DNA are
consistent with a binding mode involving insertion of the
extendedπ-systems of Ru-DHA, Ru-THA, and Ru-BIP
into the minor groove, giving a positive signal for the
transitions in the 260-280 nm ligand y-polarized region and
probably a negative signal for the 240-255 nm z-polarized
region.
The CD changes observed for double-helical DNA modi-
fied by the Ru(II) arene compounds also correlate with the
results of DNA unwinding (Figure 7 and Table 1) and
competitive EtBr displacement (Figure 6) experiments. The
monofunctional adducts of Ru-BIP, Ru-DHA, or Ru-THA
are considerably more efficient in DNA-EtBr fluorescence
quenching and in DNA unwinding than those of Ru-CYM.
One plausible explanation for this observation may be an
associated large additional contribution to fluorescence
quenching and unwinding from intercalation of the ex-
tended arene ligand of the compounds Ru-BIP, Ru-DHA,
or Ru-THA into the duplex or from other types of
DNA Modifications by Ru(II) Arene Complexes Biochemistry, Vol. 42, No. 39, 200311551
noncovalent interaction of these complexes with DNA upon
their monofunctional binding. The large unwinding angles
of 15 or 19° produced by the platinum compoundsci -[Pt-
(NH3)2(N3-ethidium)Cl]2+ andcis-[Pt(NH3)2(N8-ethidium)-
Cl]2+, respectively, which incorporate the well-known DNA
intercalator ethidium and which can form only monofunc-
tional adducts with DNA, have been explained in this way
(28). Thus, the arene moiety in the monofunctional adducts
of the compounds Ru-BIP, Ru-DHA, and Ru-THA could
be geometrically well positioned to intercalate between the
base pairs of the helix, so producing also the induced CD
bands (Figure 5). Consistent with this conclusion is the
observation that the adducts of the compound Ru-CYM,
which (like Ru-BEN) produces no induced CD bands in
the visible spectrum and quenches DNA-EtBr fluorescence
only slightly, unwinds DNA only by 7° (Figure 7D, Table
1), a similar behavior to that of the monofunctional adducts
of [Pt(dien)Cl]Cl [unwinding angle 6° (28)]. Thus, the results
of unwinding experiments support the view that the arene
ligand in Ru-BIP, Ru-DHA, and Ru-THA interacts
substantially with the double helix upon coordination of the
ruthenium complex. Hence, these results strengthen the case
for combined intercalative and monofunctional binding
modes which may be facilitated by the fluxionality of the
arene ligand in these complexes (40). On the other hand, it
seems reasonable to suggest that thep-cymene and benzene
ligands in the compounds Ru-CYM do not interact with
the double helix in a similar way, thus also supporting a
different DNA binding mode for these compounds in
comparison with the other three Ru(II) arene complexes
studied in the present work.
The arene-purine hydrophobic interactions and/or arene-
base stacking involved in the binding of the arene compounds
to double-helical DNA may also affect its melting behavior.
Previously, three factors have been invoked to account for
the thermal stability of DNA modified by ruthenium and
platinum complexes: stabilizing effects of the positive charge
on the ruthenium and platinum moieties and of DNA
interstrand cross-links, and a destabilizing effect of confor-
mational distortions such as intrastrand cross-links induced
in DNA by ruthenium and platinum coordination. At least
two additional factors may be involved in DNA stabilization
by intercalators: (i) favorable stacking interactions between
the base residues and the intercalator, and (ii) the separation
of negative backbone charges inherent to intercalation (due
to elongation and unwinding of DNA), that is, changes in
solvent structure and the counterion distribution around the
phosphate groups which may help to overcome electrostatics
unfavorable for the hybridization of the strands of the duplex
(46, 47). The dependence of the transition melting temper-
ature of DNA modified by nonintercalating platinum or
ruthenium drugs on ionic strength can be explained by
competing electrostatic effects as the salt concentration is
varied (48). Under the incubation conditions, we expect all
Ru(II) arene complexes to have produced monofunctional
adducts so that the effect of interstrand cross-links need not
be considered. Thus, the observed change in melting tem-
perature will reflect the relative proportion and contribution
of all limiting binding modes. Inherently, we predict that
conformational distortions due to the formation of the adducts
will destabilize the helix, as has been consistently observed
in earlier studies with various ruthenium and platinum
compounds.
At low ionic strength (0.01 M), it is reasonable to conclude
that the increases intm due to the modification of DNA by
Ru-BIP, Ru-DHA, or Ru-THA (Figure 8A-C) are caused
by the positive charges on ruthenium{(arene)Ru(en)}+
moieties and by the intercalation. An interesting and as yet
unresolved question, therefore, is why the modification of
DNA by these three Ru(II) arene compounds appears to result
in smaller thermal stabilization or even destabilization if the
melting curves are measured at high salt concentrations. It
is possible that the smaller increase or decrease intm due to
the modification by the compounds Ru-BIP, Ru-DHA, and
Ru-THA and observed at high ionic strength is a conse-
quence of conformational changes induced by the adducts
of these Ru(II) arene compounds that then compensate more
efficiently the “stabilizing” effects. At high salt concentration
the stabilizing effects due to the modification of DNA by
Ru-BIP, Ru-DHA, or Ru-THA are reduced, since the
electrostatic effects of these compounds are apparently
lowered with increasing concentration of Na+ counterions.
As pointed out above, the melting behavior of DNA
modified by the compound Ru-CYM is different (cf. parts
A-C and D of Figure 8). Modification by Ru-CYM already
decreasestm at low concentrations of Na+, indicating that
the effects of the factors responsible for the thermal stabiliza-
tion of DNA are noticeably reduced. As also mentioned
above, two factors have been invoked to account for the
increase of the thermal stability of DNA due to the
modification by Ru(II) arene complexes: stabilizing effects
of the positive charge on the ruthenium atom and those
associated with intercalation of the arene ligand in these
ruthenium compounds into the duplex. Hence, it seems
reasonable to conclude that the effect of one or both these
factors is markedly reduced so that the destabilization effect
of conformational alterations induced by Ru-CYM pre-
dominates already at low salt concentrations. The results are
consistent with the formation of a monofunctional adduct
of Ru-CYM with DNA (coordination to G N7) and the
absence of intercalation, as expected for this substituted
single-ring arene ligand. Hence, the stabilization of DNA
typical of intercalators (vide supra) would not be effective,
for obvious reasons. In addition, the stabilizing effects of
the positive charge on the ruthenium atom of the compound
Ru-CYM might be considerably reduced due to a substan-
tially different location of the ruthenium atom in the adduct
of Ru-CYM relative to the DNA sugar-phosphate back-
bone. This location might be unfavorable from the viewpoint
of the efficiency of the positive charge on the ruthenium
atom to neutralize negative charges of DNA phosphate
groups. The suggestion that the positive charge on the
ruthenium atom in the adducts of Ru-CYM does not
markedly contribute to the thermal stability of DNA is also
consistent with the observation that the lowering of the
melting temperature of DNA due to modification by Ru-
CYM is almost independent of the Na+ concentration (Figure
8D). Thus, the solution behavior of the DNA adducts of
Ru(II) arene complexes appears interesting and merits further
study.
Circular dichroism and polarographic analyses of DNA
modified by Ru(II) arene anticancer compounds (Figures 4,
5, and 9) demonstrate that the formation of the monofunc-
tional adducts of these complexes distorts the DNA confor-
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mation. The compounds Ru-BIP, Ru-DHA, or Ru-THA,
which contain arene ligands with extendedπ-systems, induce
nondenaturational alterations in DNA. On the other hand,
the adducts of Ru-CYM, which contains a single arene ring
but with methyl and bulky isopropyl substituents, distort
DNA more severely, so that even denaturational changes may
occur. The mechanisms underlying the biological effects of
antitumor metal-based drugs may also involve further
“downstream” effects of damaged DNA. These effects
include processing of DNA adducts of these compounds by
cellular components, for example, recognition of the adducts
by specific proteins, and their repair (49, 50). This processing
may also be affected by both the character of the confor-
mational alterations induced in DNA and the resulting
thermodynamic destabilization of this polynucleotide. For
instance, minor 1,3-intrastrand cross-links of cisplatin, which
probably do not contribute significantly to the antitumor
effects of this drug, or the same adducts of its clinically
ineffective trans isomer induce denaturational alterations in
DNA (51). On the other hand, nondenaturational alterations
occur in DNA as a consequence of the formation of the major
1,2-intrastrand cross-link of cisplatin (52). Interestingly, it
has been shown that high-mobility-group (HMG)-domain
proteins play an important role in the antitumor effect of
cisplatin in several tumor cell lines (49, 50), and while the
1,2-intrastrand cross-link of cisplatin is recognized by these
proteins (53), the 1,3-intrastrand cross-links of cisplatin or
transplatin are not (50, 53). In addition, the 1,3-intrastrand
cross-links of cisplatin are more readily removed from DNA
than its major 1,2-intrastrand cross-links (54), and it has been
shown (49, 55) that enhanced repair of the adducts of
cisplatin contributes to enhanced resistance to this drug. Thus,
an intriguing eventuality for future research is to correlate
different DNA binding modes of Ru-CYM and Ru-BEN
and the other three Ru(II) arene compounds tested in the
present work with their cytotoxicity in tumor cell lines.
In summary, the present work demonstrates that the
concept based on Ru(II) arene complexes represents an
interesting possibility for studies aimed at improving knowl-
edge of the mechanisms underlying the biological effects of
ruthenium compounds. Whether this concept is applicable
to the development of new anticancer drugs has still to be
examined.
SUPPORTING INFORMATION AVAILABLE
Flow linear dichroism spectra of CT, poly(dG-dC), and
poly(dA-dT) DNA after reaction with Ru(II) arene complexes
(Figure S1), and determination of transition polarizations of
dihydroanthracene (Figure S2). This material is available free
of charge via the Internet at http://pubs.acs.org.
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